bromocriptine

(redirected from Cycloset)
Also found in: Medical, Encyclopedia.
Related to Cycloset: bromocriptine

bro·mo·crip·tine

 (brō′mō-krĭp′tēn)
n.
An ergot alkaloid, C32H40BrN5O5, that is a dopamine antagonist and is used in its mesylate form to treat Parkinson's disease, acromegaly, and excessive prolactin secretion, and to reduce the size of certain pituitary tumors.

[bromo- + (ergo)cryptine, an ergot alkaloid (from German Ergokryptin : Ergo(t), ergot + Greek kruptos, hidden; see cryptic + -in, -in).]

bromocriptine

(ˌbrəʊməʊˈkrɪptiːn)
n
a dopamine agonist drug which blocks the release of prolactin from the pituitary gland, used in the treatment of Parkinson's disease
Translations

bromocriptine

n bromocriptina
References in periodicals archive ?
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either cycloset or placebo.
In addition, in a large T2DM study population (Cycloset Safety Trial (CST); N = 3070) comprised of subjects across a wide range of glycemic control status (Alc range: 5.5-10.5; median [25th-75th percentile]: 6.8 [6.2-7.6]) whose hyperlipidemia and hypertension were well controlled and yet with preexisting CVD history (33% of population), intervention with this agent resulted in a 40% hazard risk reduction of a prespecified composite CVD endpoint over a period of one year [24].
name of Cycloset tablet, from S2 Therapeutics and VeroScience, at five
Now, the company's product portfolio offers 22 marketed products, including XIFAXAN, UCERIS, GLUMETZA, APRISO, ZEGERID, MOVIPREP, RELISTOR, SOLESTA, FULYZAQ, CYCLOSET and DEFLUX.
rights to Cycloset and plans to start selling the drug in November.
manufacturing and marketing rights to Cycloset, a diabetes drug it expects to launch in November.
Cycloset. www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/ index.cfm?fuseaction=Search.Label ApprovalHistory#apphist.
The Food and Drug Administration in the United States approved Cycloset, maker VeroScience Inc.
(7) In the Cycloset Safety Study, for instance, bromocriptine QR combined with standard diabetes therapy (diet plus oral hypoglycemic agents as needed) was compared with standard diabetes therapy plus placebo in more than 3,000 patients.
M2 PHARMA-November 15, 2010-Santarus launches Type 2 diabetes drug CYCLOSET in USA(C)2010 M2 COMMUNICATIONS